Results 121 to 130 of about 165,965 (304)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties

Medicina
As an incretin hormone, Glucagon-like peptide-1 (GLP-1) has obvious effects on blood glucose regulation and weight loss. GLP-1 receptor (GLP-1R) agonists are synthetic products that have similar effects to GLP-1 but are less prone to degradation, and ...
Chenqi Lu, Cong Xu, Jun Yang
doaj   +1 more source

Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

BMC Medicine
• To determine whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs). • Is there a direct association between GLP-1RAs and SSIBs?
Jianxing Zhou, You Zheng, Baohua Xu, S. Long, Li-e Zhu, Yunhui Liu, Chengliang Li, Yifan Zhang, Maobai Liu, Xuemei Wu   +9 more
semanticscholar   +1 more source

Bioinorganic Site‐Specific Conjugation of Multi‐Arm Linkers to Create Pharmaceuticals With Targeting and Effector Functions

Journal of the Chinese Chemical Society, EarlyView.
This Account showcases a modular, multi‐arm linker platform that decouples payload loading from antibody conjugation. By leveraging a computationally designed ACPGHA zinc‐binding motif, we demonstrate the construction of homogeneous antibody‐drug conjugates and theranostic antibody‐radionuclide conjugates with high payload loading. The multi‐arm linker
Cédric Grauffel, Tse Wen Chang, Carmay Lim   +2 more
wiley   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

A framework for integrating health‐related social needs education into electronic health record clinical pathways

Journal of Hospital Medicine, EarlyView.
Abstract Health‐related social needs (HRSN) significantly influence patient outcomes, yet they are rarely integrated into point‐of‐care decision‐making. We developed a process to embed HRSN‐informed and HRSN‐targeted care recommendations directly into three electronic health record‐integrated high‐use clinical pathways—cirrhosis, diabetes, and ...
Karthik Warke Rohatgi, Siddhi Nadkarni, Nisarg Shah, Lou Hart, Dan Heacock, Shaili Gupta   +5 more
wiley   +1 more source

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants

Frontiers in Pharmacology
BackgroundObesity is a chronic inflammatory disease with high morbidity that is decidedly prevalent worldwide and in Saudi Arabia. Glucagon-like peptide 1 receptor agonists (GLP-1 agonists) are broadly used for the management of diabetes and obesity.
Amirah Alhowiti, Hyder Mirghani, Abdulaziz Abdulrahman Qrmli, Amal Abdullah Albalawi, Raneem Abdulrahman Aljohani   +4 more
doaj   +1 more source

Standardized MRI‐Based Quantification of Epicardial Adipose Tissue Volume: Reproducibility and Agreement With Cardiac Computed Tomography

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Epicardial adipose tissue volume (EATV) is increasingly recognized as a cardiometabolic risk marker associated with adverse outcomes. The most established approach for EATV quantification is cardiac computed tomography (CT). MRI offers a radiation‐free alternative allowing simultaneous assessment of myocardial function and tissue ...
Judith Gronwald, Svante S. Gersch, Zoé Böttiger, Clara Hagedorn, Torben Lange, Sören J. Backhaus, Sebastian Kelle, Constanze Schmidt, Karl Toischer, Andreas Schuster, Alexander Schulz   +10 more
wiley   +1 more source

Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials

BMC Endocrine Disorders
Objective To evaluate the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obesity among children and adolescents.
Qirong Chen, Haixia Liu, Jie Xu, Yu Zhou, Junying Ma   +4 more
doaj   +1 more source

GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease

International Journal of Molecular Sciences
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. Recent data highlight similarities between neurodegenerative diseases, including PD and type 2 diabetes mellitus (T2DM), suggesting a crucial interplay between the gut–brain ...
K. Kalinderi, Vasileios Papaliagkas, Liana Fidani   +2 more
semanticscholar   +1 more source

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source